Dendreon (NASDAQ: [[ticker:DNDN]])
Cash on hand: $287.5 million
Related Xconomy coverage:
“Dendreon Saga Heads Toward Climax, As Cancer Drug Aims to Prove It Prolongs Lives”
“No Devil in Details: Dendreon Data Stands Up to Scrutiny from Doctors, Investors”
“Dendreon Goes on Hiring Binge After Prostate Cancer Drug Boosts Survival”
“Dendreon Drug Works, But Can It Manufacture Enough to Meet Demand?”
“Dendreon Tames Short Sellers, Transforms Itself into Old-School Buy-and-Hold Stock”
“Dendreon May Not Survive Its Success: Q&A with Founder Chris Henney, Part 1”
MDRNA (NASDAQ: [[ticker:MRNA]])
Cash on hand: $9.4 million
Related Xconomy coverage:
“MDRNA Cuts Executive Pay, Freezes Salaries as Cash Runs Out”
“MDRNA Pays Off $5.5M Debt”
“MDRNA Nabs $7.25M From Novartis”
Omeros (NASDAQ: [[ticker:OMER]])
Cash on hand: $10.4 million
Related Xconomy coverage:
“Omeros Plans to Test Waters with First Washington IPO in Two Years, Sources Say”
“Omeros Moves Closer To IPO, Sets Price Goal”
OncoGenex Pharmaceuticals (NASDAQ: [[ticker:OGXI]])
Cash on hand: $5.7 million
Related Xconomy coverage:
“OncoGenex, Toiling in Dendreon’s Shadow, Scopes Out Partners For Prostate Cancer Drug”
“OncoGenex Raises $9.5M”
“OncoGenex Drug Helps Prostate Cancer Patients Live Longer in Small Study”
“Prostate Cancer Drug Vaults OncoGenex Onto Investor Radar Screens”
|
||||||
Oncothyreon (NASDAQ: [[ticker:ONTY]])
Cash on hand: $22.7 million
Related Xconomy coverage:
“Goodbye Cancer Vaccines, Hello Cancer Drugs: Oncothyreon Reinvents Itself”
“Oncothyreon Sells Off Stimuvax, Cuts Jobs, Facilities To Preserve Cash”
“Oncothyreon Raises $15M”
Seattle Genetics (NASDAQ: [[ticker:SGEN]])
Cash on hand: $189.9 million
Related Xconomy coverage:
“Seattle Genetics, Bucking the Trend, Recruits Hodgkin’s Patients at Warp Speed”
“Seattle Genetics “Empowered Antibody” Shines at Blood Disease Meeting”
“Seattle Genetics Defies Gravity With Biotech’s First Underwritten Stock Sale in Six Months”
“Seattle Genetics Gets $136M Total”
